Salvage chemotherapy in metastatic colorectal cancer with the combination of capecitabine and mitomycin C

Abstract

A significant proportion of heavily pretreated patients with metastatic colorectal cancer maintain good performance status (PS) and are eligible for further systemic treatment. Mitomycin C (MMC) combined with capecitabine can be considered as salvage treatment in this group of patients. To evaluate the efficacy and toxicity of mitomycin C and capecitabine as at least third-line systemic therapy (after failure of 5Fu, irinotecan, oxaliplatin-based chemotherapy regimens and targeted therapies) in patients with metastatic colorectal cancer. A total of 31 patients with a median age of 55.2 years with metastatic colorectal cancer received salvage chemotherapy at the

Further Therapeutic Options in Heavily Pretreated Colorectal Cancer Patients

“…Toxicity of capecitabine plus MMC combination is mild, acceptable, and easily manageable, and no significant hematological AEs have been reported thus far [71,[73][74]. The main non-hematological AEs documented in patients treated with this regimen are palmar-plantar erythema, nausea, diarrhea, and fatigue [71,[73][74].…”

“…The majority of patients received previously two, three, or even four lines of anticancer therapy. Median PFS varied between 1.7 and 5.4 months [68][69][70][71]74] and median OS between 5.4 and 13 months [68][69][70][71][72]74]. While those results might be considered disappointing, it should be emphasized that all patients were pretreated with many lines of systemic therapy and had metastases in multiple locations.…”